Gulf Coast TX
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
Oct 16 (Reuters) -- Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious kidney condition, citing "strategic consideration…
